Tian Yangyang, Yang Yang, Zhang Xiaowei, Nakajima Takero, Tanaka Naoki, Sugiyama Eiko, Kamijo Yuji, Lu Yu, Moriya Kyoji, Koike Kazuhiko, Gonzalez Frank J, Aoyama Toshifumi
Department of Metabolic Regulation, Shinshu University Graduate School of Medicine, Matsumoto, 390-8621, Japan.
Department of Neurosurgery, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050000, China.
Glycoconj J. 2016 Dec;33(6):927-936. doi: 10.1007/s10719-016-9703-1. Epub 2016 Jun 18.
Sulfatides, a type of glycosphingolipid, are associated with carcinogenesis. Peroxisome proliferator-activated receptor α (PPARα) is involved in the regulation of sulfatide metabolism as well as in cancer development. We previously reported that transgenic (Tg) mice expressing hepatitis C virus core protein (HCVcp) exhibited age-dependent PPARα activation and carcinogenesis in liver. However, the metabolism of sulfatides in hepatocellular carcinoma is unknown. To examine the relationship between sulfatide metabolism, carcinogenesis, HCVcp, and PPARα, age-dependent changes of these factors were examined in HCVcpTg, PPARα inhibitor-treated HCVcpTg, and non-Tg mice. The sulfatide content in liver, the hepatic expression of two key enzymes catalyzing the initial and last reactions in sulfatide synthesis, the hepatic expression of known sulfatide-transferring protein, oxidative stress, and hepatic PPARα expression and its activation were age-dependently increased in HCVcpTg mice. The increased synthesis and accumulation of sulfatides and PPARα activation were significantly enhanced in liver cancer lesions. These changes were attenuated by PPARα inhibitor treatment and not observed in non-Tg mice. These results suggest that HCVcp-induced age-dependent PPARα activation increases synthesis of sulfatides and the resulting sulfatide accumulation affects HCV-related liver cancer. The monitoring of hepatic sulfatide content and the modulation of sulfatide generation by intervention using a PPARα inhibitor might be useful for the prediction and prevention of HCV-related hepatocarcinogenesis, respectively.
硫脂是一种糖鞘脂,与致癌作用相关。过氧化物酶体增殖物激活受体α(PPARα)参与硫脂代谢的调节以及癌症发展过程。我们之前报道过,表达丙型肝炎病毒核心蛋白(HCVcp)的转基因(Tg)小鼠在肝脏中表现出年龄依赖性的PPARα激活和致癌作用。然而,肝细胞癌中硫脂的代谢情况尚不清楚。为了研究硫脂代谢、致癌作用、HCVcp和PPARα之间的关系,我们检测了HCVcpTg小鼠、用PPARα抑制剂处理的HCVcpTg小鼠和非Tg小鼠中这些因素的年龄依赖性变化。HCVcpTg小鼠肝脏中的硫脂含量、催化硫脂合成起始和终末反应的两种关键酶的肝脏表达、已知硫脂转运蛋白的肝脏表达、氧化应激以及肝脏PPARα表达及其激活均呈年龄依赖性增加。硫脂合成和积累的增加以及PPARα激活在肝癌病变中显著增强。这些变化通过PPARα抑制剂处理而减弱,在非Tg小鼠中未观察到。这些结果表明,HCVcp诱导的年龄依赖性PPARα激活增加了硫脂的合成,而由此产生的硫脂积累影响了HCV相关的肝癌。监测肝脏硫脂含量以及使用PPARα抑制剂进行干预调节硫脂生成可能分别有助于预测和预防HCV相关的肝癌发生。